CDTX News and Press, Cidara Therapeutics Inc. From 03/07/19

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45 th Annual European Society for Blood and Marrow Transplantation (EBMT) ...

Shares of Cidara Therapeutics ( CDTX ) have lost over 60% of their value since my November 2017 article suggested that it could outperform soon. So far in 2019, the stock price has risen by over 25% (decent bounce along with the rest of the biotech sector). Despite operating in an unloved...

Cidara Therapeutics (NASDAQ: CDTX ): Q4 GAAP EPS of -$0.44  beats by $0.15 . More news on: Cidara Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2018 and provided an update on it...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming ...

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be h...

Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other im...

Thinly traded micro cap Cidara Therapeutics (NASDAQ: CDTX ) is up  30%  premarket on light volume on the heels of its announcement of results from the Phase 2 STRIVE study evaluating once-weekly intravenous rezafungin in patients with candidemia and/or invasive candidiasis (yea...

STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s ...